

Strategic agreement secured with LYPHE GROUP to streamline UK medicinal cannabis prescription volumes

- **LYPHE GROUP engaged as Bod's preferred dispenser for Project Twenty21 – Europe's largest medicinal cannabis registry**
- **LYPHE GROUP is the UK's leading medicinal cannabis service provider and distributor – it is the UK's busiest telehealth service, has physical clinics across the country and over 20 prescribing physicians writing over 50% of all new cannabis prescriptions in the UK market**
- **Agreement will help build brand awareness amongst patients and physicians allowing for significant growth in MediCabilis™ sales**
- **UK cannabis market is estimated to grow to \$3Bn in value by 2024ⁱ and 4 times the size of the Australian market by 2028ⁱⁱ – providing significant opportunity for Bod**

Sydney, Australia – 1 September 2020: Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited ("Bod", or "the Company") (ASX: BDA) has secured a strategic agreement with medicinal cannabis services provider and distributor LYPHE GROUP ("LYPHE") (www.lyphegroup.com).

Under the agreement, LYPHE will act as Bod's preferred dispenser for Project Twenty21. Project Twenty21 is Europe's largest medicinal cannabis registry targeting 20,000 patients (refer ASX announcement: 8 November 2019). The agreement has no fixed term and can be terminated by either party giving six months' notice in writing.

LYPHE is the UK's leading medicinal cannabis service provider and distributor. The group is made up of a number of vertically integrated companies that provide patient focused medicinal cannabis solutions to UK consumers.

LYPHE the UK's busiest medicinal cannabis prescriber, providing telehealth services as well as operating from physical clinic locations across the country. The group has over 20 prescribing physicians writing over 50% of all new cannabis prescriptions in the UK market.

This agreement is pivotal for Bod's growing focus on the UK medicinal cannabis market and the Company's participation in Project Twenty21. Bod is confident that its partnership with LYPHE will ensure the most efficient process to dispense its medicines.

Bod will leverage LYPHE's established footprint in the UK market, its distribution channels and network of physicians to fill the large number of prescriptions that are expected to be generated from Project Twenty21 patients. First prescriptions for Project Twenty21 participants have already been filled (refer ASX announcement: 11 May 2020) and the Company looks forward to providing an update on growth in the near term.

Bod will also utilise the partnership to build opportunities outside of Project Twenty21, allowing it to further penetrate the UK private market. The UK presents a large market opportunity for the Company and Bod is confident operations in the country will scale up in the coming months.

CEO Jo Patterson said: "This is a great partnership, which will help Bod streamline its medicinal cannabis sales through Project Twenty21. LYPHE will ensure Bod's participation in Project Twenty21 will provide patients with seamless and efficient access to Bod's MediCabilis™ products.

"LYPHE is a respected operator in the UK cannabis sector and this agreement will allow Bod to build further brand awareness with patients in the country. This is of particular importance, as many medicinal cannabis users from the private market are fast becoming part of Project Twenty21.

Bod is a cannabis centric healthcare company. With a global focus and a mission to innovate and transform the way we live and enjoy life. Delivering premium, proven and trusted products for both the consumer markets and medical markets. Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications with education, research and knowledge.

CAPITAL STRUCTURE

ASX code **BDA**
 Shares on issue 91.4m
 Market Capitalisation ~\$26.5m

BOARD & MANAGEMENT

Mr Mark Masterson
 Non-Executive Chairman

Ms Jo Patterson
 Chief Executive Officer

Mr Akash Bedi
 Non-Executive Director

Mr George Livery
 Non-Executive Director

Mr Patrice Malard
 Non-Executive Director

Mr Simon O'Loughlin
 Non-Executive Director

Mr Stephen Kelly
 Company Secretary

CONTACT

Level 1, 377 New South Head Rd
 Double Bay, NSW 2028

T +612 9199 5018

E info@bodaustralia.com.au

“We are achieving consistent growth through our medicinal cannabis operations in Australia and the UK and we look forward to highlighting this progress to shareholders in the near term.”

LYPHE’s CEO, Dean Friday added: *“We are thrilled to have entered a partnership with a company of the calibre of Bod Australia. LYPHE has a growing network of clinics and physicians prescribing medicinal cannabis across the United Kingdom and we are excited to be offering Bod’s MediCabilis® products to patients enrolled in Project Twenty21.*

“The UK market continues to grow at an accelerating rate, and we are noticing a significant shift in patients using medicinal cannabis to treat a range of debilitating conditions. We have no doubt that MediCabilis™ will be well received by our physicians and patient base.”

This release has been authorised by the Board of Directors of Bod Australia Limited.

- ENDS -

ABOUT BOD AUSTRALIA

Bod Australia Limited (ASX:BDA) Bod is a cannabis centric healthcare company.

With a global focus and a mission to innovate and transform the way we live and enjoy life.

Delivering premium, proven and trusted products for both the consumer markets and medical markets.

Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications through education, research and trials.

For more information please contact:

Jo Patterson
Chief Executive Officer
info@bodaustralia.com
+61 2 9199 5018

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 431 271 538

¹ The UK Cannabis Report – December 2019 – Prohibition Partners

ⁱⁱ The European Cannabis Report, fourth edition 2019 – Prohibition Partners